Abstract
Patients with rosacea have a higher incidence of depression, embarrassment, social phobia, stress, subjective disease perception and decreased quality of life. Sexual dysfunction is one of the main factors contributing to impaired life quality. The aim of this study is to evaluate the presence of sexual dysfunction in women with rosacea. A prospective case-control study was planned to investigate female sexual dysfunction in patients utilizing the Female Sexual Function Index (FSFI). A total of 85 patients with rosacea and 80 healthy control subjects were included in the study. The total FSFI scores were significantly lower in the rosacea group than in the control group (26.6 vs. 27.6, p < 0.001, respectively). According to the total FSFI scores, 49.4% of the rosacea patients had sexual dysfunction compared with 30.0% of the healthy controls (p = 0.011). The total FSFI scores were negatively correlated with the values of the Dermatologic Life Quality Index (DLQI) (r: −0.251, p = 0.001), disease duration (r: −0.416, p < 0.001), age (r: −0.632, p < 0.001) and body mass index (r: −0.329, p < 0.001). Sexual dysfunction in female rosacea patients was demonstrated in this study. We believe that the recognition of sexual dysfunction in women with rosacea will provide improvements in the life quality of such patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
World Health Organization. Defining sexual health: report of a technical consultation on sexual health. Geneva: WHO; 2002.
World Health Organization. Division of Mental Health and Prevention of Substance Abuse. WHOQoL: measuring quality of life. Geneva: World Health Organization; 1997.
Ermertcan AT. Sexual dysfunction in dermatological diseases. J Eur Acad Dermatol Venereol. 2009;23:999–1007.
Pluchino N, Carmignani A, Cubeddu A, Santoro A, Cela V, Errasti T. Androgen therapy in women: for whom and when. Arch Gynecol Obstet. 2013;288:731–7.
Kim YH, Kim SM, Kim JJ, Cho IS, Jeon MJ. Does metabolic syndrome impair sexual function in middle- to old-aged women? J Sex Med. 2011;8:1123–30.
Basra MK, Finlay AY. The family impact of skin disease: the Greater Patient concept. Br J Dermatol. 2007;156:929–37.
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72:749–58.
Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78:156–66.
Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22:179–84.
Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2012;9:1497–507.
Kalmbach DA, Kingsberg SA, Ciesla JA. How changes in depression and anxiety symptoms correspond to variations in female sexual response in a nonclinical sample of young women: a daily diary study. J Sex Med. 2014;11:2915–27.
Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24:2387–92.
Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584–7.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practicalmeasure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.
Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol. 2006;45:1300–7.
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional selfreport instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.
Aygin D, Aslan FE. The Turkish adaptation of the female sexual function index. Turkiye Klinikleri J Med Sci. 2005;25:393
Cabral PU, Canario AC, Spyrides MH, Uchôa SA, Eleutério J Jr, Gonçalves AK. Determinants of sexual dysfunction among middle-aged women. Int J Gynaecol Obstet. 2013;120:271–4.
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.
Song SH, Jeon H, Kim SW, Paick JS, Son H. The prevalence and risk factors of female sexual dysfunction in young korean women: an internet-based survey. J Sex Med. 2008;5:1694–701.
Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol. 2014;28:1165–9.
Bewley A, Fowler J, Schofer H, Kerrouche N, Rives V. Erythema of rosacea health-related quality of life: results of a meta-analysis. Dermatol Ther. 2016;6:237–47.
Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71:973–80.
Bohm D, Schwanitz P, Stock Gissendanner S, Schmid-Ott G, Schulz W. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med. 2014;19:586–91.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537–44.
Laumann EO, Niclsi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40–80 years: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res. 2005;17:39–57.
Dennerstein L, Alexander JL, Kotz K. The menopause and sexual functioning: a review of the population-based studies. Annu Rev Sex Res. 2003;14:64–82.
Oberg K, Fugl-Meyer AR, Fugl-Meyer KS. On categorization and quantification of women’s sexual dysfunctions: an epidemiological approach. Int J Impot Res. 2004;16:261–9.
Cayan S, Akbay E, Bozlu M, Canpolat B, Acar D, Ulusoy E. The prevalence of female sexual dysfunction and potential risk factors that may impair sexual function in Turkish women. Urol Int. 2004;72:52–57.
Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health. 1999;53:144–8.
Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual difficulty and dysfunction? J Sex Med. 2006;3:589–95.
Bachmann G. Female sexuality and sexual dysfunction: are we stuck on the learning curve? J Sex Med. 2006;3:639–45.
Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause. 2004;11:120–30.
Dalpiaz O, Kerschbaumer A, Mitterberger M, Pinggera GM, Colleselli D, Bartsch G, et al. Female sexual dysfunction: a new urogynaecological research field. BJU Int. 2008;101:717–21.
Miner M, Esposito K, Guay A, Montorsi P, Goldstein I. Cardiometabolic risk and female sexual health: the Princeton III summary. J Sex Med. 2012;9:641–51.
Enzlin P, Rosen R, Wiegel M, Brown J, Wessells H, Gatcomb P, et al. Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/EDIC study cohort. Diabetes Care. 2009;32:780–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Aktaş Karabay, E., Karşıyakalı, N. & Karabay, E. Evaluation of sexual functions in female rosacea patients: a prospective, case-control study. Int J Impot Res 32, 628–634 (2020). https://doi.org/10.1038/s41443-020-0275-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-020-0275-z